OS Therapies announced that their OST-HER2 immunotherapy achieved a 71.2% three-year overall survival rate in a Phase 2b trial for metastatic osteosarcoma, significantly higher than the 45.8% survival in historical controls (p=0.002). This promising result supports early market access applications with regulators including the FDA, EMA, MHRA, and TGA, targeting commercial availability in 2027. The company also secured $3.15 million in VAT refunds and expects an additional $7.2 million in tax credits to fund a confirmatory Phase 3 trial in the UK. OST-HER2 holds multiple FDA and EMA designations, enhancing its regulatory pathway and potential for accelerated approval.
Russia has introduced new electricity rules requiring cryptocurrency mining farms to connect under Category 4 power supply, which has lower priority and allows authorities to cut power during shortages. This aims to protect electricity availability f...
TRON founder Justin Sun announced that the blockchain is prepared to deploy its quantum-resistant security layer on the mainnet at any time, aiming to protect against emerging threats from quantum computing and AI advancements. This upgrade follows c...
In the past five hours, Ether (ETH) saw the largest inflow of $48.73 million and also the biggest outflow of $8.32 million among cryptocurrencies. Bitcoin (BTC) followed with $22.47 million inflows and $7.43 million outflows. Stablecoins like USDT an...
Over the past seven days, centralized cryptocurrency exchanges experienced a combined net outflow of 14,978.95 Bitcoin (BTC). Binance led this trend with a significant outflow of 16,455.52 BTC, followed by Coinbase Pro with 4,034.39 BTC leaving the p...
Solana's network economics have improved, with token holder net income exceeding $400,000 for two consecutive weeks as SOL traded near $109 on October 11. This marks a recovery after three weeks of negative results, indicating that network activity g...
